Macular degeneration—both age-related (AMD) and inherited forms—involves progressive death of photoreceptor cells (rods and cones) in the central retina.
Macular degeneration—both age-related (AMD) and inherited forms—involves progressive death of photoreceptor cells (rods and cones) in the central retina. In AMD, a combination of lipid accumulation (drusen), oxidative stress, and chronic inflammation triggers degeneration of the retinal pigment epithelium (RPE), the supportive layer feeding photoreceptors. In inherited retinal dystrophies, genetic mutations directly compromise photoreceptor function or survival. Cell therapy approaches aim to replace lost photoreceptors or RPE cells using fetal-stage stem cells, placental MSCs, or induced pluripotent stem cell (iPSC)-derived retinal cells. These cell types can differentiate into photoreceptors or RPE in controlled environments. The proposed mechanism involves transplantation of functional cells into the macula, where they integrate into damaged retinal circuits and restore light sensitivity and signal transmission to the brain.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €9,200–€27,600 (stemconnect.io) |
| Main cell types studied | Fetal Stem Cells, MSCs from Amniotic Membrane |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 44 · 8 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Forty-four completed or ongoing clinical trials in macular degeneration and inherited retinal diseases employ cell-based approaches, with 8 active trials enrolling. Early human trials have used fetal retinal tissue, placental MSCs, and more recently iPSC-derived photoreceptor precursors and RPE cells. Safety data are emerging—transplanted cells are generally tolerated, with few reports of immune rejection or severe inflammation. Functional improvements (visual acuity, light sensitivity, visual fields) have been measured in small cohorts, showing stabilisation of vision loss in some participants and modest gains in best-corrected acuity in others (typically ≤3 lines on an eye-chart). No large phase III trial has yet demonstrated a definitive vision-restoration threshold.
Depending on assessment, a Macular Degeneration & Vision protocol may draw on:
Cell therapy for macular degeneration remains expensive and largely experimental. Treatment costs range from €6,000 to €15,000+ per eye, reflecting iPSC derivation, long-term cell expansion, quality-control testing, and the technical complexity of subretinal or intravitreal injection. Baseline and follow-up imaging (optical coherence tomography [OCT], visual field testing, electroretinography) adds €2,000–4,000. The condition typically affects both eyes, so bilateral treatment approaches €15,000–30,000.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Macular Degeneration & Vision cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Macular Degeneration & Vision.
Full Macular Degeneration & Vision FAQ → · Macular Degeneration & Vision cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita